24-Apr-2024
No headlines found.
Business Wire (Mon, 22-Apr 8:52 AM ET)
Guardant Health to Report First Quarter 2024 Financial Results on May 9, 2024
Business Wire (Thu, 18-Apr 4:05 PM ET)
Business Wire (Wed, 3-Apr 8:05 AM ET)
Business Wire (Wed, 13-Mar 5:00 PM ET)
Guardant Health Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Business Wire (Wed, 6-Mar 4:30 PM ET)
Business Wire (Fri, 1-Mar 5:30 AM ET)
Business Wire (Thu, 22-Feb 4:05 PM ET)
Guardant Health to Participate in Upcoming Investor Conferences
Business Wire (Thu, 15-Feb 4:05 PM ET)
Guardant Health to Report Fourth Quarter and Full Year 2023 Financial Results on February 22, 2024
Business Wire (Thu, 1-Feb 4:05 PM ET)
Guardant Health, Inc, based in Redwood City, California, is a leader in liquid-based cancer tests for clinical and research use. The company offers Guardant360 LDT, a liquid biopsy test for treatment selection in advanced stage cancer, Guardant360 CDx, an FDA-approved companion diagnostic for several targeted therapies, and Guardant OMNI, a broader gene panel for immuno-oncology research. In 2021, Guardant launched Reveal, a tumor-agnostic molecular residual disease, or MRD, test. In 2022, the company launched a lab-developed test version of Shield, a liquid biopsy for colorectal cancer, or CRC, screening. Additionally, Guardant offers research development services such as regulatory approval consultancy and clinical trial referrals.
Guardant Health trades on the NASDAQ stock market under the symbol GH.
As of April 24, 2024, GH stock price climbed to $18.10 with 1,543,610 million shares trading.
GH has a beta of 1.54, meaning it tends to be more sensitive to market movements. GH has a correlation of 0.09 to the broad based SPY ETF.
GH has a market cap of $2.20 billion. This is considered a Mid Cap stock.
Last quarter Guardant Health reported $155 million in Revenue and -$.64 earnings per share. This beat revenue expectation by $5 million and exceeded earnings estimates by $.23.
In the last 3 years, GH stock traded as high as $169.43 and as low as $15.81.
The top ETF exchange traded funds that GH belongs to (by Net Assets): VTI, VB, IWM, VXF, VBK.
GH has underperformed the market in the last year with a price return of -26.2% while the SPY ETF gained +24.2%. GH has also underperformed the stock market ETF in the last 3 month and 2 week periods returning -21.1% and -5.7%, respectively, while the SPY returned +4.6% and -2.7%, respectively.
GH support price is $16.49 and resistance is $18.19 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that GH stock will trade within this expected range on the day.